Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YL211
- Development stage
- Phase 1
- Lead developer
- MediLink Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
YL211 is a next-generation antibody-drug conjugate (ADC) that specifically targets c-Met (also known as mesenchymal-epithelial transition factor), a receptor tyrosine kinase overexpressed or mutated in many tumor cell types. By binding to c-Met on the surface of cancer cells, YL211 delivers a cytotoxic payload directly to these cells, inhibiting their proliferation and survival. The drug also induces a bystander effect on neighboring tumor cells, further enhancing its anti-tumor activity. Developed for the treatment of advanced solid tumors, YL211 is currently being evaluated in Phase 1 clinical trials[1][2][3][4][5][7].
- Other names
- anti-c-Met ADC YL211anti-c-Met/TOP1i ADC YL211anti-c-Met/TOP1i antibody-drug conjugate YL211
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on YL211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YL211.